VVRA-TM 002

VVRA-TM 002 is an investigational sublingual formulation being developed by Vivera Biosciences (a division of Vivera Pharmaceuticals) for the treatment of central nervous system disorders, specifically focused on opiate/opioid cessation and deterrence. The drug utilizes Vivera's proprietary, patented TABMELT sublingual drug delivery system, which allows the active therapeutic compound to dissolve under the tongue. This sublingual route is designed to bypass the gastrointestinal tract and first-pass liver metabolism, potentially offering faster onset, improved bioavailability, and more precise dosing compared to traditional oral administration.